PMID- 35173988
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220219
IS  - 2150-0878 (Print)
IS  - 2150-0886 (Electronic)
IS  - 2150-0878 (Linking)
VI  - 13
IP  - 1
DP  - 2022 Jan
TI  - Emerging Treatment Options for Advanced or Recurrent Endometrial Cancer.
PG  - 45-59
LID - 10.6004/jadpro.2022.13.1.4 [doi]
AB  - Endometrial cancer is the most common cancer of the female reproductive organs. 
      The American Cancer Society estimates that there will be over 65,950 new cases 
      diagnosed in 2022. According to the National Comprehensive Cancer Network (NCCN) 
      Guidelines, response rates in the front-line setting are approximately 40% to 
      62%. Prior to the recent U.S. Food and Drug Administration (FDA) approvals of 
      immunotherapy, there had been no standard of care for women after failing 
      front-line carboplatin and paclitaxel. In May 2017, the FDA approved single-agent 
      pembrolizumab in microsatellite instability high (MSI-H)/mismatch repair 
      deficient (dMMR) endometrial cancer patients following failure of systemic 
      therapy. Then, in September 2019, the FDA approved pembrolizumab and lenvatinib 
      for women who are not MSI-H or are MMR-proficient. This approval was based on 
      KEYNOTE-146 and Study 111. Among 94 non-MSI-H women, 80% of those treated with 
      pembrolizumab and lenvatinib had tumor shrinkage, and 38.3% had objective 
      response by RECIST 1.1 as assessed by an independent radiology committee. The 
      median duration of response was not reached, with 69% being progression free at 6 
      months. Grade 3/4 treatment-related adverse events (AEs) occurring in > 20%, 
      including fatigue, hypertension, and gastrointestinal AEs. With supportive care, 
      early identification, and intervention, the side effect profile was manageable, 
      with only 21% discontinuing treatment due to AEs.
CI  - (c) 2022 Harborside.
FAU - Halla, Kimberly
AU  - Halla K
AD  - Arizona Oncology Associates PC, Phoenix, Arizona.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220201
PL  - United States
TA  - J Adv Pract Oncol
JT  - Journal of the advanced practitioner in oncology
JID - 101550346
PMC - PMC8805805
COIS- The author has no conflicts of interest to disclose.
EDAT- 2022/02/18 06:00
MHDA- 2022/02/18 06:01
PMCR- 2022/01/01
CRDT- 2022/02/17 05:36
PHST- 2022/02/17 05:36 [entrez]
PHST- 2022/02/18 06:00 [pubmed]
PHST- 2022/02/18 06:01 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 2022.13.1.4 [pii]
AID - 10.6004/jadpro.2022.13.1.4 [doi]
PST - ppublish
SO  - J Adv Pract Oncol. 2022 Jan;13(1):45-59. doi: 10.6004/jadpro.2022.13.1.4. Epub 
      2022 Feb 1.